London, UK-based Mereo BioPharma Group has appointed Richard Jones as chief financial officer and member of the board of directors, effective from early 2017.
Jones joins the rare and specialty diseases clinical-stage company from Shield Therapeutics, where he most recently served as chief financial officer and company secretary.
Prior to this, Jones worked in investment banking and specialised in advising healthcare clients. He held a number of senior positions as Brewin Dolphin Securities, Investec and PricewaterhouseCoopers.
Dr Denise Scots-Knight, chief executive of Mereo BioPharma, said: “I am delighted to announce the appointment of Richard Jones as our chief financial officer and to the board of directors.
“His extensive financial experience in healthcare industry, initially as an investment banker in the sector and more recently as chief financial officer of Shield Therapeutic, complements that of the other members of Mereo’s executive team.
“Following our positive debut as a listed company, the board is confident that Richard will make a valuable and significant contribution to Mereo’s future success.”